ARTH News 0.3000 Arch Therapeutics Inc. (ARTH)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arch Therapeutics Inc. (ARTH) 0.3000 $ARTH

Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff
Marketwire - Tue Apr 01, 7:03AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Chirag Shah, PhD as Vice President of Research and Development Engineering and Quality Systems, effective April 7, 2014, and has appointed Peter A. LaCrosse as Chief of Staff, effective immediately.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March
Marketwire - Wed Mar 26, 8:03AM CDT
Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, presents his work using AC5(TM) at two scientific meetings.

IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:

Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 8:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST.

10-Q: ARCH THERAPEUTICS, INC.
Edgar Online - Fri Feb 14, 7:42AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Arch Therapeutics Secures $2.85 Million Private Placement
Marketwire - Mon Feb 10, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care has closed a previously announced private placement to accredited individual and institutional investors (the "Investors" .

OTC Daily Alert Stock Watch - Arch Therapeutics, Inc. (OTCQB: ARTH)
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Arch Therapeutics Announces $2.85 Million Private Placement
Marketwire - Fri Jan 31, 5:00AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce today its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share, pursuant to the terms of a securities purchase agreement dated January 30, 2014. The private placement is expected to close on or about February 4, 2014, subject to customary closing conditions.

Arch Therapeutics Presents 2014 Milestones During Live Webcast
Marketwire - Wed Jan 22, 10:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., presented its calendar year 2014 milestone targets during a live audio and high-definition video webcast on Wednesday, January 22 at 10:30AM Eastern Time from the Noble Financial Capital Markets' Tenth Annual Equity Conference in South Florida.

Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
Marketwire - Tue Jan 14, 8:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22 at 10:30AM Eastern Time.

Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
Marketwire - Wed Jan 08, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Terrence W. Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST. Attendees will find the presentation scheduled for "Track C" in the Mission II room at that time. Dr. Norchi's presentation will provide insights into the Company's ongoing activities to commercially develop novel technologies into a suite of new products targeting markets of unmet clinical need.

Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27
Marketwire - Fri Sep 20, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the Boulder Peptide Symposium 2013. The conference is being held September 25-27, 2013, at the St Julien Hotel in Boulder, Colorado.

Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Marketwire - Tue Sep 03, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference. The conference, sponsored by H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.

Arch Therapeutics Announces Plans for Upcoming Activities
Marketwire - Tue Aug 06, 2:06PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to provide a brief review of proposed future activities.

Arch Therapeutics Reports on Current Activities
Marketwire - Tue Jul 30, 8:02AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to provide a summary of current events.

OTC Daily Alert Stock Watch
WorldStockWire - Thu Jul 25, 1:46AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland
Marketwire - Tue Jul 23, 8:51AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a lecture titled "The Spider Effect, how the Immune System in the Brain can be Measured and Modulated with Nanotechnology" at the 6th annual European Foundation for Clinical Nanomedicine (CLINAM) Summit in Basel, Switzerland.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece
Marketwire - Tue Jul 16, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a keynote lecture titled "Translating Nanomedicine: Molecular medical devices from Nano Neuro Knitting to Immediate Hemostasis to Cancer Stem Cell Arrest" in Corfu, Greece at the Technology Transfer Workshop: From the Lab to the Marketplace.

ARTH, XUII, AAMRQ and SCRC added to OTC Active Stock Watch List at GSR
ACCESSWIRE - Tue Jul 16, 8:01AM CDT
New York, NY - (ACCESSWIRE) - 07/16/2013 - Growing Stock Report initiates its OTC Active Stock Watch List adding Arch Therapeutics, Inc. (OTC:ARTH), Xumanii (OTC:XUII), AMR Corporation (OTC:AAMRQ) and ScripsAmerica, Inc. (OTC:SCRC)

BIZM, ARTH, AAMRQ and SGLB added to Active OTC Watch List at EPR
ACCESSWIRE - Thu Jul 11, 8:06AM CDT
New York, NY - (ACCESSWIRE) - (07/11/2013) - Equity Profile Report initiates an Active OTC Watch List adding Biozoom, Inc. (OTC:BIZM), Arch Therapeutics, Inc. (OTC:ARTH), AMR Corporation (OTC:AAMRQ) and Sigma Labs, Inc. (OTC:SGLB).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 94

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 130

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 29

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 72

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 0

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 10

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 50

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading

Top 5 Most Recently Viewed Articles

Ragie Launches Advanced Agent Ready Features for Developers

Updated Category News Views 253

Ragie Introduces Innovative Agent Ready Features Ragie is excited to present its latest advancement: the introduction of Agent Ready capabilities. This launch focuses on empowering developers with tools for creating intelligent, context-aware agents. Enhanced features like Agentic Retrieval and support for Right-to-Left (RTL) languages enhance accessibility and robust...

Continue Reading
JNR Stellarc 100K: A Game-Changer in Refillable Vapes

Updated Category News Views 200

Introducing the JNR Stellarc 100K Refillable Vape JNR has officially launched the JNR Stellarc 100K, a remarkable modular refillable vape system that promises to redefine the vaping experience. Engineered for extreme endurance and superior safety features, the Stellarc 100K is set to offer unparalleled value to its users. This advanced vape is not just another product; it...

Continue Reading
Xiao-I Corporation Shareholders Encouraged to Join Class Action

Updated Category News Views 86

Xiao-I Corporation Shareholders Encouraged to Join Class Action Recent events have led to significant concerns for shareholders of Xiao-I Corporation. With allegations of misleading statements and inadequate disclosures surfacing, many shareholders find themselves at a crossroads. It is essential for investors who purchased shares during a specific period to explore their...

Continue Reading
Assessing Bristol Myers Squibb: Analyst Insights and Future Prospects

Updated Category News Views 138

Bristol Myers Squibb: A Low Valuation Opportunity BofA Securities has recently upgraded Bristol Myers Squibb Co. (NYSE: BMY) from a Neutral position to a Buy rating, indicating a positive outlook for the company driven by strong near-term catalysts. Analyst Jason Gerberry highlighted a compelling risk-reward scenario, especially as the company anticipates a flat...

Continue Reading
Carrier's Q3 Performance and Future Outlook: Key Insights

Updated Category News Views 237

Carrier Global Corporation's Q3 Earnings Overview Carrier Global Corporation (NYSE: CARR), a prominent innovator in climate and energy solutions, recently released its third-quarter earnings, showcasing performance that exceeded market expectations. The results highlight not only the financial stability of the company but also the strategic adjustments made to navigate...

Continue Reading